Coronavirus disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has become an immense threat to global public health. In this study, we performed complete genome sequencing of a SARS-CoV-2 isolate. More than 67,000 genome sequences were further inspected from Global Initiative on Sharing All Influenza Data (GISAID). Using several in silico techniques, we proposed prospective therapeutics against this virus. Through meticulous analysis, several conserved and therapeutically suitable regions of SARS-CoV-2 such as RNA-dependent RNA polymerase (RdRp), Spike (S) and Membrane glycoprotein (M) coding genes were selected. Both S and M were chosen for the development of a chimeric vaccine that can generate memory B and T cells. siRNAs were also designed for S and M gene silencing. Moreover, six new drug candidates were suggested that might inhibit the activity of RdRp. Since SARS-CoV-2 and SARS-CoV-1 have 82.30% sequence identity, a Gene Expression Omnibus (GEO) dataset of Severe Acute Respiratory Syndrome (SARS) patients were analyzed. In this analysis, 13 immunoregulatory genes were found that can be used to develop type 1 interferon (IFN) based therapy. The proposed vaccine, siRNAs, drugs and IFN based analysis of this study will accelerate the development of new treatments.

由严重急性呼吸系统综合症冠状病毒-2 (SARS-CoV-2) 引起的 2019 冠状病毒病 (COVID-19) 已成为对全球公共卫生的巨大威胁。在这项研究中，我们对 SARS-CoV-2 分离株进行了完整的基因组测序。全球流感数据共享倡议 (GISAID) 进一步检查了 67,000 多个基因组序列。使用多种计算机技术，我们提出了针对这种病毒的前瞻性疗法。通过细致的分析，选择了 SARS-CoV-2 的几个保守且适合治疗的区域，例如 RNA 依赖性 RNA 聚合酶 (RdRp)、刺突 (S) 和膜糖蛋白 (M) 编码基因。 S 和 M 都被选中用于开发能够产生记忆 B 和 T 细胞的嵌合疫苗。 siRNA 还被设计用于 S 和 M 基因沉默。此外，六种新候选药物被认为可能抑制 RdRp 的活性。由于 SARS-CoV-2 和 SARS-CoV-1 具有 82.30% 的序列同一性，因此对严重急性呼吸综合征 (SARS) 患者的基因表达综合 (GEO) 数据集进行了分析。在此分析中，发现了 13 个免疫调节基因，可用于开发基于 1 型干扰素 (IFN) 的疗法。本研究提出的基于疫苗、siRNA、药物和 IFN 的分析将加速新疗法的开发。